Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

I just came across updated data on perioperative IDHi #vorasidenib and #ivosidenib in IDH1-mutated diffuse glioma presented at #SNO24. As someone who used to be heavily involved in early clinical development I am really delighted to see continuing progress. www.onclive.com/view/periope...

@US_FDA approves #Futibatinib for FGFR2+ Advanced #CCA. It’s been a great 2 years for BTC survivors with addition of #durvalumab + gem/cis as well as #ivosidenib (IDH1) #infigratinib #pemigatinib (FGFR2 fusion) #dabrafenib #trametinib (BRAF V600E)

@ILCAnews @MacarullaTeresa
3 @US_FDA & EMA approved #CCA targeted rx #pemigatinib #ivosidenib #dabrafenib #trametinib Unfortunately #NGS which identifies targeted rx underutilized & often not reimbursed. #NGS endorsed by @myESMO for all #CCA #ILCA22 @CCA_Alliance @curecc